China News Online, December 11 (Chen Jing, Wang Guangzhao, Zhu Yu) Chinese multidisciplinary experts work together to build an online and offline diagnosis and treatment platform to provide high-quality diagnosis and treatment for patients from all over the world. However, the Chinese expert team is working hard to explore Experts are introduced to the platform to explore treatment options for related diseases that are more suitable for Chinese people through different perspectives from East and West.

At the same time, many experts have joined hands to incorporate research data on Chinese patients, compile relevant guidelines, and form a "Chinese plan" for treatment.

　　In an interview with reporters on the 11th, Professor Ye Dingwei, Chairman of the Committee on Urology and Male Reproductive System Tumors of the Chinese Anti-Cancer Association and Professor Ye Dingwei from Fudan University Affiliated Tumor Hospital revealed that the cross-regional multidisciplinary comprehensive diagnosis and treatment (MDT) online platform-"China Urinary Tumor MDT Platform" We are working to introduce a team of top international urological oncology experts.

At present, 3 batches of 31 top international experts have joined the platform.

Many of these experts come from 25 world-class medical centers such as Memorial Sloan Kettering Cancer Center and Anderson Cancer Center.

The expert called on experts from different countries and disciplines to participate in the prevention and treatment of urinary tumors, so as to gather various forces to formulate precise treatment strategies for different races.

　　"There are significant differences between Asian populations and western populations in terms of genomics such as tumor typing and genetic susceptibility. Among Chinese prostate cancer patients, the proportion of advanced patients is high, and the mortality rate is high, showing completely different incidence characteristics from European and American countries. "Professor Ye Dingwei introduced to reporters, "This has led to differences in clinical efficacy and safety in the diagnosis and treatment of prostate cancer between Eastern and Western populations; the inclusion of top international experts in the'China Urinary Tumor MDT Platform' hopes to pass the Eastern and Western Experts from different perspectives explore more suitable urinary tumor diagnosis and treatment programs for Chinese people."

Experts call for experts from different countries and disciplines to participate in the prevention and treatment of urinary tumors, so as to gather various forces to formulate precise treatment strategies for different races.

Photo courtesy of Cancer Hospital

　　It is understood that since 2005, Fudan University Cancer Hospital has taken the lead in establishing a multidisciplinary urological tumor diagnosis and treatment team in China, bringing together experts in various fields such as tumor surgery, internal medicine, pathology, imaging, etc., from offline to online. It has provided the convenience of one-stop consultation for nearly 10,000 domestic and foreign patients.

　　In July 2016, Professor Ye Dingwei’s team took the lead in initiating and building China’s cross-regional multidisciplinary comprehensive diagnosis and treatment (MDT) online platform-"China Urinary Oncology MDT Platform" to promote the concept of MDT throughout China and promote urology in medical institutions at all levels Oncology MDT team building.

Professor Ye Dingwei said: "We strive to promote the standardized diagnosis and treatment of pre-urinary system tumors, and form a replicable and extendable online multidisciplinary comprehensive diagnosis and treatment'model room', hoping to provide a broader space for Chinese people's precise treatment strategies for urinary tumors."

　　During the interview, the reporter learned that, among the nearly 6,000 professional users registered on the "China Urinary Oncology MDT Platform", more than 2,500 are urological oncologists who routinely participate in platform activities.

The platform has established 4 regional centers, including the North Center—Peking University First Hospital, the South Center—Sun Yat-sen University Cancer Center, the Eastern Center—Fudan University Cancer Hospital, and the Western Center—West China Hospital of Sichuan University.

The platform has so far radiated to 147 urban medical centers, covering almost all provinces (autonomous regions and municipalities) across the country.

　　On the same day, the patient, Mr. Xu, came to the Multidisciplinary Outpatient Department of Urinary Oncology, Fudan University Affiliated Tumor Hospital.

He told reporters that nine months ago, during the epidemic, an online multidisciplinary consultation allowed him to obtain a plan jointly developed by many top experts.

After treatment, Mr. Xu's condition was obviously under control.

　　While exploring the most suitable treatment options for Chinese patients, the reporter learned that at the 10th Urinary Oncology International Forum just held, the multidisciplinary comprehensive diagnosis and treatment guidelines for prostate cancer based on the Chinese population "CSCO Prostate Cancer Diagnosis and Treatment Guidelines" (abbreviated as: Guidelines) ) Came out.

Professor Ye Dingwei said that this version of the Multidisciplinary Comprehensive Diagnosis and Treatment Guidelines for Prostate Cancer is the first to "tailor-made" treatment plans based on Chinese population research data, which means that there is a "Chinese Plan" for multidisciplinary standardized comprehensive treatment of prostate cancer.

　　It is reported that the current level of diagnosis and treatment of prostate cancer in China is unbalanced. The current guidelines for prostate cancer treatment quote data mostly from the research results of Western countries, and there is a lack of research based on Chinese data.

The guide published this time was led by Professor Ye Dingwei, gathered more than 80 experts from dozens of top urinary tumor diagnosis and treatment centers across the country, and was compiled based on data from the Chinese population.

Based on the consensus of the international cutting-edge prostate cancer diagnosis and treatment guidelines, the experts widely quoted the research results of prostate cancer based on the Chinese population. The subjects involved covered urology, diagnostic radiology, pathology, radiotherapy, nuclear medicine, etc. The Chinese have provided precise and standardized multidisciplinary treatment of prostate cancer personalized plans.

(Finish)